Timothy J Henderson

This inventor holds 20 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 14 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Sharp + Dohme Corp., Msd R&d (China) Co., Ltd., Elexopharm Gmbh. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy J Henderson. Retrieved from https://idiyas.com/inventor/timothy-j-henderson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 2)

% Patents Active = 95.0

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 11.8

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Edison, NJ (US) (2013 - 2015)
New Providence, NJ (US) (2018)
Gainesville, FL (US) (2019)
Natick, MA (US) (2018 - 2024)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 10

Msd R&d (China) Co., Ltd.

Merck Msd (r&d) China Co., Ltd.

patent

5. 1 out of 9

Msd International Gmbh

patents

6. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

KRAS Inhibitors

STING Agonists

A2A Antagonists

PRMT5 Inhibitors

Allosteric Modulators

Cyclic Di-nucleotide

Expandable Roasting Platform

Heterobicyclo-compounds

Diazeniumdiolate Derivatives

Aldosterone Synthase Inhibitors

M4 Muscarinic Receptor

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297208 - Small molecule inhibitors of KRAS G12C mutant (2025-05-13),

2. 12291538 - Small molecule inhibitors of KRAS G12C mutant (2025-05-06),

3. 12173026 - PRMT5 inhibitors (2024-12-24),

4. 11970479 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2024-04-30),

5. 11697657 - Small molecule inhibitors of KRAS G12C mutant (2023-07-11),

6. 11339156 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2022-05-24),

7. 11046714 - 2,2-difluorodioxolo Areceptor antagonists (2021-06-29),

8. 10981902 - 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-04-20),

9. 10793557 - Sting agonist compounds (2020-10-06),

10. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

11. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

12. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

13. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

14. 10414747 - Benzo[b]thiophene compounds as sting agonists (2019-09-17),

15. 10357130 - Expandable roasting platform (2019-07-23),

Title: Innovator Spotlight: Timothy J. Henderson

Introduction

Timothy J. Henderson, located in Natick, MA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 20 patents. His work focuses on developing innovative therapeutic solutions, particularly in cancer treatment.

Latest Patents

His latest patents include groundbreaking compounds that serve as small molecule inhibitors of the KRAS G12C mutant. The disclosure details compounds of Formula (I) or pharmaceutically acceptable salts that inhibit the G12C mutant of the Kirsten rat sarcoma (KRAS) protein. These compounds are expected to be utilized as therapeutic agents for cancer treatment. The disclosures also encompass pharmaceutical compositions that include these compounds and outline methods for their use in cancer therapy and prophylaxis.

Career Highlights

Timothy has held key positions in influential organizations such as Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His innovative contributions have played a pivotal role in advancing pharmaceutical research and development.

Collaborations

Throughout his career, Timothy has collaborated with esteemed colleagues, including Ryan D. Otte and Michael Man-Chu Lo. Together, they have contributed to the advancement of cutting-edge therapeutics, focusing on addressing complex health issues.

Conclusion

Timothy J. Henderson's work exemplifies the intersection of science and innovation, pushing the boundaries of therapeutic possibilities. With a strong record of patents and collaborations in renowned companies, he continues to be a driving force in the pharmaceutical industry, particularly in developing solutions for cancer treatment.

Profile summary based on public USPTO records.